Concentration data from 1,134 subjects in 11 clinical studies ( eight phase I , one phase II , and two phase III ) were used to perform a population PK analysis , including estimation of the bioavailability and quantification of the effects of P-glycoprotein ( P-gp ) inhibitors as well as renal impairment on edoxaban PK .